The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Phase 4 Recruiting
46 enrolled
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Phase 3 Recruiting
500 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
Morpheus-panBC
Phase 1/2 Recruiting
792 enrolled
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Phase 1/2 Recruiting
316 enrolled
ELEGANCE
Recruiting
2,766 enrolled
OPERA-02
Phase 3 Recruiting
1,000 enrolled
NoLEEta
Phase 3 Recruiting
3,902 enrolled
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Phase 3 Recruiting
1,050 enrolled
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Phase 2 Recruiting
80 enrolled
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Phase 3 Recruiting
920 enrolled
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Phase 2 Recruiting
120 enrolled
CAROLEEN
Recruiting
3,250 enrolled
PIKALO-1
Phase 1/2 Recruiting
720 enrolled
Adjuvant WIDER
Phase 3 Recruiting
1,400 enrolled
FourLight-3
Phase 3 Recruiting
1,020 enrolled
RaPhLRR
Phase 2 Recruiting
200 enrolled
CYCAD-1
Phase 1/2 Recruiting
564 enrolled
IMPULSE
Recruiting
240 enrolled